BioAge Labs Future Growth
Future criteria checks 0/6
BioAge Labs's earnings are forecast to decline at 16.7% per annum. EPS is expected to grow by 53.7% per annum.
Key information
-16.7%
Earnings growth rate
53.7%
EPS growth rate
| Pharmaceuticals earnings growth | 18.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Oct 2024 |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -121 | -119 | -113 | 1 |
| 12/31/2025 | N/A | -132 | -136 | -124 | 1 |
| 12/31/2024 | N/A | -83 | -96 | -92 | 1 |
| 6/30/2024 | N/A | -62 | -48 | -48 | N/A |
| 3/31/2024 | N/A | -66 | -43 | -43 | N/A |
| 12/31/2023 | N/A | -64 | -38 | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Y7G is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: Y7G is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: Y7G is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if Y7G's revenue is forecast to grow faster than the German market.
High Growth Revenue: Y7G is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if Y7G's Return on Equity is forecast to be high in 3 years time